Monday 23 June 2025
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Forthcoming Events
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • GeneLink recruits Monte Taylor

GeneLink recruits Monte Taylor

18 July 2001

GeneLink has recruited Monte Taylor, who will become director ofbusiness development.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news

Today's issue

Vertex presents positive data for zimislecel in type 1 diabetes
Pharmaceutical
Vertex presents positive data for zimislecel in type 1 diabetes
23 June 2025
Biotechnology
Positive new data on Roche’s Lunsumio and Polivy combo
23 June 2025
Pharmaceutical
Innovative medicines: where does the Netherlands stand?
23 June 2025
Pharmaceutical
New data on Novo’s next-gen obesity drugs and hemophilia challenger
23 June 2025
Pharmaceutical
Achieve adds vapers to smokers in targeting multi-billion dollar market
23 June 2025
Pharmaceutical
The week in pharma: action, reaction and insight – week to June 20
22 June 2025
Biotechnology
MHRA approves UK’s first anti-PD-1 MAb for aggressive form of lung cancer
21 June 2025

Company Spotlight

A Danish biotech company focused on the discovery and development of peptide-based medicines.






The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom

  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin

Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze